Innovative Pharmaceutical Biotech (HKSE:00399) EBIT : HK$209.96 Mil (TTM As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech EBIT?

Innovative Pharmaceutical Biotech's earnings before interest and taxes (EBIT) for the six months ended in Sep. 2024 was HK$217.21 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was HK$209.96 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Innovative Pharmaceutical Biotech's annualized ROC % for the quarter that ended in Sep. 2024 was -0.73%. Innovative Pharmaceutical Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Innovative Pharmaceutical Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was 10.07%.

Innovative Pharmaceutical Biotech EBIT Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech EBIT Chart

Innovative Pharmaceutical Biotech Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

-75.42

-21.12

226.38

-20.70

316.80

Innovative Pharmaceutical Biotech Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
EBIT	Get a 7-Day Free Trial															-7.67	-13.04	324.06	-7.25	217.21

Competitive Comparison of Innovative Pharmaceutical Biotech's EBIT

For the Specialty Retail subindustry, Innovative Pharmaceutical Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innovative Pharmaceutical Biotech's EV-to-EBIT Distribution in the Retail - Cyclical Industry

For the Retail - Cyclical industry and Consumer Cyclical sector, Innovative Pharmaceutical Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Innovative Pharmaceutical Biotech's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Innovative Pharmaceutical Biotech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$209.96 Mil.

Innovative Pharmaceutical Biotech (HKSE:00399) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Innovative Pharmaceutical Biotech's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

	ROC % (Q: Sep. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2024 )	+	Invested Capital (Q: Sep. 2024 ))	/ count )
=	-14.17 * ( 1 - 0% )	/	( (1717.209	+	2177.073)	/ 2 )
=	-14.17	/	1947.141
=	-0.73 %

where

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1383.023	-	47.616	-	( 3.075	-	max(0, 391.601	-	9.799	+	3.075	))
=	1717.209

	Invested Capital		(Q: Sep. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1378.866	-	48.151	-	( 0.428	-	max(0, 852	-	5.642	+	0.428	))
=	2177.073

Note: The Operating Income data used here is two times the semi-annual (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Innovative Pharmaceutical Biotech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2024		Q: Sep. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	434.412	/	( ( (0 + max(-48.63, 0))	+	(0 + max(-54.67, 0)) )	/	2 )
=	434.412	/	( ( 0	+	0 )	/	2 )
=	434.412	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(4.905	+	0	+	1.607)	-	(47.616	+	0	+	7.526)
=	-48.63

	Working Capital		(Q: Sep. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(3.372	+	0	+	0)	-	(48.151	+	0	+	9.8910000000001)
=	-54.67

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Innovative Pharmaceutical Biotech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2024 )
	=	209.955	/	2085.446
	=	10.07 %

Innovative Pharmaceutical Biotech EBIT Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative Pharmaceutical Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

145 Hennessy Road, Unit No. 2002, 20th Floor, On Hong Commercial Building, Wan Chai, Hong Kong, HKG

Website

http://www.ipb.asia

Innovative Pharmaceutical Biotech Ltd is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The company has two operating segments; Trading of beauty products in Hong Kong and Research, development, and commercialisation of the oral insulin product. The company generates almost all of its revenue from Hong Kong.

Executives

Mao Yumin	2101 Beneficial owner
Chau Yiu Ting	2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Mao Yumin	2101 Beneficial owner
Chau Yiu Ting	2101 Beneficial owner

Innovative Pharmaceutical Biotech Headlines

No Headlines